成大生物(688739) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 139,028.74 million, a decrease of 17.06% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was RMB 13,761.67 million, down 59.86% year-on-year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 4,599.98 million, a decline of 85.79%[4] - Basic earnings per share decreased to RMB 0.33, down 60.24% from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 975,181.82 million, a decrease of 2.98% from the beginning of the period[5] - Equity attributable to shareholders of the parent company was RMB 935,998.52 million, down 2.12% from the beginning of the period[5] Market and Operational Factors - The decline in revenue was primarily due to changes in the domestic rabies vaccine market environment and increased competition[5] - Increased asset impairment losses were due to the termination of the hib vaccine project and full impairment of capitalized R&D investments[5] - The company experienced growth in overseas sales revenue and managed to control selling and administrative expenses effectively[5] Financial Data Disclaimer - Investors are advised to note that the financial data is preliminary and subject to final confirmation in the annual report[7]